I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Efficacy, patient-reported outcomes, and safety of the anti..:
Buckley, Christopher D
;
Simón-Campos, Jesus A
;
Zhdan, Vyacheslav
...
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study / C. D Buckley, J. A. Simón-Campos,V. Zhdan [et al.] // The Lancet Rheumatology. – 2020. – Vol. 2, № 11. – P. 677–688. – Режим доступу до журн. : https://doi.org/10.1016/S2665-9913(20)30229-0.. , 2020
Link:
http://repository.pdmu.edu.ua/handle/123456789/14003
RT Journal T1
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
UL https://suche.suub.uni-bremen.de/peid=base-ftumsacademija:oai:repository.pdmu.edu.ua:123456789_14003&Exemplar=1&LAN=DE A1 Buckley, Christopher D A1 Simón-Campos, Jesus A A1 Zhdan, Vyacheslav A1 Becker, Brandon A1 Davy, Katherine A1 Fisheleva, Elena A1 Gupta, Anubha A1 Hawkes, Carol A1 Inman, David A1 Layton, Mark A1 Mitchell, Nina A1 Patel, Jatin A1 Saurigny, Didier A1 Williamson*, Russell A1 Tak, Paul P A1 Ждан, Вячеслав Миколайович PB Copyright© 2020 Elsevier Ltd. All rights reserved YR 2020 JF Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study / C. D Buckley, J. A. Simón-Campos,V. Zhdan [et al.] // The Lancet Rheumatology. – 2020. – Vol. 2, № 11. – P. 677–688. – Режим доступу до журн. : https://doi.org/10.1016/S2665-9913(20)30229-0. LK http://repository.pdmu.edu.ua/handle/123456789/14003 DO http://repository.pdmu.edu.ua/handle/123456789/14003 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)